Valentina Boni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina Boni has a total of 464 co-authors. Here are the top co-authors by number of shared publications:
- Sherene Loi
Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia
28 shared publications - Victor Moreno
START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
28 shared publications - Andrés Cervantes
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
27 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - James J. Harding
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
23 shared publications - Joohyuk Sohn
Yonsei Cancer Center, Seoul, Republic of Korea
21 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Open AccessDabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 14 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
Purpose: CB307 is a trispecific variable heavy-chain antibody fragment against prostate-specific membrane antigen (PSMA), CD137, and human serum albumin. It is designed to mitigate hepatotoxicity by activating T cells only in PSMA-positive tumors and to increase drug half-life through albumin binding. This phase I study investigated the safety and tolerability of CB307 as monotherapy or in combination with pembrolizumab. Patients and Methods: Patients who were heavily pretreated with PSMA-positive solid tumors were enrolled in the dose-escalation phase of CB307 monotherapy. The additional safety and efficacy of CB307 were assessed in the CB307 monotherapy expansion cohort and in combination with pembrolizumab. Results: CB307 was administered to 75 patients. CB307 was given once every 7 days as monotherapy (N = 50) or in combination with pembrolizumab (N = 25). Two dose-limiting toxicities (grade 3 transient transaminitis) were observed. A total of three grade 3 transaminitis events (one in the monotherapy cohort and two in the combination cohort) were observed, and none involved bilirubin elevation. Durable RECIST responses were observed in two patients with metastatic castration-resistant prostate cancer enrolled in the 800 mg CB307 monotherapy and in one patient in the combination cohort (overall response rates: 11.1% and 7.1%, respectively). A disease control rate (DCR) of 50% was observed in patients enrolled in the 800 mg CB307 monotherapy cohort and 42.9% in the combination cohort. In a post hoc analysis, the response was numerically better in patients who had not received chemotherapy in the 6 months prior to starting CB307 (ORR = 20%, DCR = 60% vs. ORR = 0%, DCR = 37.5%). CB307 induces cytotoxic cell expansion in tumors and PD-L1 expression. Conclusions: CB307 was well tolerated as a monotherapy and in combination with pembrolizumab, and tumor responses were observed in patients with metastatic castration-resistant prostate cancer.
- 14 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
Purpose: CB307 is a trispecific variable heavy-chain antibody fragment against prostate-specific membrane antigen (PSMA), CD137, and human serum albumin. It is designed to mitigate hepatotoxicity by activating T cells only in PSMA-positive tumors and to increase drug half-life through albumin binding. This phase I study investigated the safety and tolerability of CB307 as monotherapy or in combination with pembrolizumab. Patients and Methods: Patients who were heavily pretreated with PSMA-positive solid tumors were enrolled in the dose-escalation phase of CB307 monotherapy. The additional safety and efficacy of CB307 were assessed in the CB307 monotherapy expansion cohort and in combination with pembrolizumab. Results: CB307 was administered to 75 patients. CB307 was given once every 7 days as monotherapy (N = 50) or in combination with pembrolizumab (N = 25). Two dose-limiting toxicities (grade 3 transient transaminitis) were observed. A total of three grade 3 transaminitis events (one in the monotherapy cohort and two in the combination cohort) were observed, and none involved bilirubin elevation. Durable RECIST responses were observed in two patients with metastatic castration-resistant prostate cancer enrolled in the 800 mg CB307 monotherapy and in one patient in the combination cohort (overall response rates: 11.1% and 7.1%, respectively). A disease control rate (DCR) of 50% was observed in patients enrolled in the 800 mg CB307 monotherapy cohort and 42.9% in the combination cohort. In a post hoc analysis, the response was numerically better in patients who had not received chemotherapy in the 6 months prior to starting CB307 (ORR = 20%, DCR = 60% vs. ORR = 0%, DCR = 37.5%). CB307 induces cytotoxic cell expansion in tumors and PD-L1 expression. Conclusions: CB307 was well tolerated as a monotherapy and in combination with pembrolizumab, and tumor responses were observed in patients with metastatic castration-resistant prostate cancer.